Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

MediRX vs Vea Health

MediRX
Graded #206

Higher grade

vs+11.099999999999994
Vea Health
Graded #450

Lower grade

The verdict

MediRX takes it — 66.1/100 to 55/100.

MediRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. MediRX is a telehealth weight-loss platform offering compounded GLP-1 injections — semaglutide starting at $149/month and tirzepatide starting at $199/month — plus NAD+ and a name-brand GLP-1 option.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMediRX +19
64
45
Dose & formulationMediRX +26
77
51
Clinical oversightMediRX +16
82
66
Labs & monitoringMediRX +1
53
52
FulfillmentMediRX +5
73
68
Contract termsVea Health +35
20
55
MediRX · left barVea Health · right bar

The numbers

MetricMediRXVea Health
WeighScore66.1/10055/100
GradeCC
Scorecard rank#206#450
Semaglutide$149/mo (compounded)Not disclosed
Tirzepatide$199/mo (compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
MediRX

Graded #206 · C

Strengths

  • LegitScript Certified — a meaningful trust signal for an online pharmacy
  • Named operating entity disclosed (MediRX, Inc., Wyoming)
  • Care and pharmacy fulfillment run on OpenLoop Health's licensed network
  • Low promotional first-month pricing — semaglutide first month as low as $70

Where it loses points

  • Doesn't publish the exact states it serves; telehealth rules vary by state
  • Ongoing monthly price rises after the promotional first month
  • Compounded semaglutide and tirzepatide injections — limited oral options
  • Specific compounding pharmacies aren't named beyond the OpenLoop network
Vea Health

Graded #450 · C

Strengths

  • Publishes the FDA compounded-medication disclaimer
  • Oral and injection protocols for both semaglutide and tirzepatide
  • Claims 50-state coverage via a clinician network
  • Clearly differentiated positioning (longevity, men's health, performance)

Where it loses points

  • Pricing not shown until after sign-up
  • Pharmacy partner not named (only 'U.S.-based pharmacy')
  • LegitScript certification status not visible
  • No named medical director
  • 503A vs 503B designation not specified

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard